Researchers at Trinity College Dublin, the Tallaght Institute of Memory and Cognition and St James’s Hospital, Dublin, are exploring the ability of a new blood test, plasma p-tau217, to detect Alzheimer’s disease (AD). This test could potentially replace the current diagnostic method, a lumbar puncture/spinal tap (which is invasive and poses risks and challenges) in over half of patients with early symptoms, thus allowing more patients to be diagnosed more accurately and with greater efficiency.
The study was recently published in the journal Alzheimer’s & Dementia: Diagnosis, Assessment and Disease Monitoring.
In Ireland, over 60,000 people live with dementia, with Alzheimer’s disease accounting for about 70 per cent of cases. In order to enable accurate diagnosis, biomarkers are currently measured in cerebrospinal fluid (CSF) obtained using a diagnostic lumbar puncture (LP) procedure. Of those in Ireland currently living with Alzheimer’s disease, up to half do not have a formal diagnosis, highlighting the need for improved diagnostic methods which are accurate and can be used at scale.
The study is one of the first in Europe to examine the ‘real-world’ performance of one of the leading automated blood tests for Alzheimer’s disease, plasma p-tau217, in patients with mild symptoms undergoing assessment in a specialist memory service. 148 patients attending Tallaght University Hospital (TUH) generously donated blood and cerebrospinal fluid (CSF) samples at the time of their LP, enabling researchers to directly compare new blood tests to established CSF biomarkers.
Crucially, this was performed using fully-automated technology (Lumipulse), which already exists in clinical diagnostic laboratories. The use of a fully-automated system increases reliability over time in the laboratory as well as reliability between different laboratories.
The study found that measuring plasma p-tau217 using a fully-automated system was >90% as accurate as results obtained from LP. Integrating the blood test into clinical pathways could potentially avoid the need for over half of diagnostic LPs. This has clear implications for the diagnosis and management of early Alzheimer disease, said the authors.
From their results, the research team believe that this new blood test could replace over half of the 150-200 diagnostic LP procedures that they currently carry out in the Tallaght Institute of Memory and Cognition every year.
Dr Jean Dunne, Chief Medical Scientist, Department of Immunology, St James’s Hospital and Trinity Translational Medicine Institute (TTMI) said: “This blood test is not available currently in Ireland and the findings from this research will lend support to making it available in the future. This ‘translation’ from a research to a diagnostic test is dependent on the scientists, the clinical teams and the support from hospital management.
“Using this automated analyser the scientists at St James’s will be able to deliver a reliable and reproducible diagnostic test result. The quality assurance carried out in the diagnostic laboratory includes comparison of results achieved to those reported internationally. All of this research will benefit the patient and the clinical teams and combines the research and diagnostic expertise to deliver a world class, patient centred service.”
